Successively, the rising importance of the prognostic role of the anti-human epidermal growth factor receptor 2 (anti-HER2) brought about the establishment of a new classification of BC and the development of new therapeutic strategies based on the molecular characteristics of each tumor [3,4,5]. This evidence concerns the gene ERBB2 and breast cancer.